Please login to the form below

Not currently logged in
Email:
Password:

Baxter appoints two new board members

Uma Chowdhry and Thomas Chen join US healthcare company

Baxter International has added Uma Chowdhry and Thomas Chen to its board of directors, effective November, 2012.

Chowdry was most recently senior VP and chief science and technology officer at science and engineering firm DuPont, before retiring in 2010 after more than 30 years of service at the company.

Other positions she held during her time there include director, DuPont engineering technology and business planning and technology director, chemicals.

Chen most recently served as senior VP, international nutrition, at Abbott, before he too retired in 2010.

During his time at Abbott career, he served in a number of roles of increasing responsibility, primarily in Pacific/Asia/Africa where he oversaw expansion into a number of emerging markets.

''The appointments of Uma and Thomas deepen the strength of the Baxter board of directors and align with our history of scientific and product innovation, and our international presence as a company,'' said Robert Parkinson, Baxter's chair and CEO.

1st October 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics